BioPorto AS (BIOPOR) - Financial and Strategic SWOT Analysis Review

November 2021 | 51 pages | ID: BC8C6124085EN
GlobalData

Abstracts

BioPorto AS (BIOPOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

BioPorto AS (BioPorto) is an in-vitro diagnostics company which offers a wide range of specialized monoclonal antibodies, antibody-based diagnostic assays, and biomarkers for the identification and management of seriously ill patients. It employs these monoclonal antibodies in its own biomarker programs. The company’s comprehensive antibodies’ portfolio serves the R&D requirements of diagnostic and pharmaceutical companies. BioPorto evaluates its biomarker candidates derived from its antibody portfolio for early detection of acute kidney injury, and mannan-binding lectin (MBL) for immune response, and also investigates potential candidates in antibiotics, and immune defense. The company distributes its products worldwide through its own sales team, distributors, and through partnership with original equipment manufacturers (OEMs). It has subsidiaries in Denmark, and the US. BioPorto is headquartered in Copenhagen, Denmark.

BioPorto AS Key Recent Developments

Nov 15,2021: BioPorto Announces Extraordinary General Meeting and New Board Member
Oct 22,2021: BioPorto Notice Convening the Extraordinary General Meeting
Oct 20,2021: BioPorto appoints new Chief Executive Officer and announces changes to the Board of Directors
Oct 20,2021: BioPorto appoints new Chief Financial Officer
Aug 18,2021: BioPorto Announces Q2 2021 Report

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

BioPorto AS - Key Facts
BioPorto AS - Key Employees
BioPorto AS - Key Employee Biographies
BioPorto AS - Major Products and Services
BioPorto AS - History
BioPorto AS - Company Statement
BioPorto AS - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
BioPorto AS - Business Description
Product Category: Antibodies
Overview
Performance
Product Category: ELISA Kits
Overview
Performance
Product Category: NGAL Revenue
Overview
Performance
Product Category: Other Products and Licenses
Performance
Product Category: Royalty
Performance
Geographical Segment: Asia
Performance
Geographical Segment: Europe
Performance
Geographical Segment: North America
Performance
Geographical Segment: Other Countries
Performance
R&D Overview
BioPorto AS - Corporate Strategy
BioPorto AS - SWOT Analysis
SWOT Analysis - Overview
BioPorto AS - Strengths
BioPorto AS - Weaknesses
BioPorto AS - Opportunities
BioPorto AS - Threats
BioPorto AS - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

BioPorto AS, Medical Equipment, Deals By Year, 2015 to YTD 2021
BioPorto AS, Medical Equipment, Deals By Type, 2015 to YTD 2021
BioPorto AS, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Nov 15, 2021: BioPorto Announces Extraordinary General Meeting and New Board Member
Oct 20, 2021: BioPorto appoints new Chief Executive Officer and announces changes to the Board of Directors
Oct 20, 2021: BioPorto appoints new Chief Financial Officer
Aug 18, 2021: BioPorto Announces Q2 2021 Report
Jul 05, 2021: Abingdon Health: Manufacturing agreement with Bioporto
May 05, 2021: Peter M?rch Eriksen resigns as CEO of BioPorto A/S
Apr 26, 2021: BioPorto initiates search for new CFO as Ole Larsen resigns
Nov 18, 2020: BioPorto announces Q3 2020 report
Aug 19, 2020: BioPorto announces q2 2020 report
May 07, 2020: BioPorto announces Q1 2020 report

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

BioPorto AS, Key Facts
BioPorto AS, Key Employees
BioPorto AS, Key Employee Biographies
BioPorto AS, Major Products and Services
BioPorto AS, History
BioPorto AS, Subsidiaries
BioPorto AS, Key Competitors
BioPorto AS, Ratios based on current share price
BioPorto AS, Annual Ratios
BioPorto AS, Annual Ratios (Cont...1)
BioPorto AS, Annual Ratios (Cont...2)
BioPorto AS, Interim Ratios
BioPorto AS, Medical Equipment, Deals By Year, 2015 to YTD 2021
BioPorto AS, Medical Equipment, Deals By Type, 2015 to YTD 2021
BioPorto AS, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

BioPorto AS, Performance Chart (2016 - 2020)
BioPorto AS, Ratio Charts
BioPorto AS, Medical Equipment, Deals By Year, 2015 to YTD 2021
BioPorto AS, Medical Equipment, Deals by Type, 2015 to YTD 2021